CN105385784A - 用于检测人乳头瘤病毒的遗传标记 - Google Patents
用于检测人乳头瘤病毒的遗传标记 Download PDFInfo
- Publication number
- CN105385784A CN105385784A CN201510671553.4A CN201510671553A CN105385784A CN 105385784 A CN105385784 A CN 105385784A CN 201510671553 A CN201510671553 A CN 201510671553A CN 105385784 A CN105385784 A CN 105385784A
- Authority
- CN
- China
- Prior art keywords
- hpv
- dna
- sequence
- primer
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001514 detection method Methods 0.000 title claims abstract description 34
- 241000701806 Human papillomavirus Species 0.000 title claims description 151
- 239000003550 marker Substances 0.000 title claims description 21
- 230000002068 genetic effect Effects 0.000 title claims description 17
- 238000000034 method Methods 0.000 claims abstract description 90
- 210000002700 urine Anatomy 0.000 claims abstract description 87
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 150000007523 nucleic acids Chemical class 0.000 claims description 68
- 108020004707 nucleic acids Proteins 0.000 claims description 53
- 102000039446 nucleic acids Human genes 0.000 claims description 53
- 125000003729 nucleotide group Chemical group 0.000 claims description 44
- 239000002773 nucleotide Substances 0.000 claims description 43
- 108091034117 Oligonucleotide Proteins 0.000 claims description 36
- 230000000295 complement effect Effects 0.000 claims description 34
- 101150029662 E1 gene Proteins 0.000 claims description 28
- 238000000926 separation method Methods 0.000 claims description 10
- 238000003745 diagnosis Methods 0.000 claims description 4
- 239000000523 sample Substances 0.000 abstract description 77
- 108090000623 proteins and genes Proteins 0.000 abstract description 41
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 94
- 238000003752 polymerase chain reaction Methods 0.000 description 79
- 238000012360 testing method Methods 0.000 description 60
- 230000003321 amplification Effects 0.000 description 32
- 238000003199 nucleic acid amplification method Methods 0.000 description 32
- 238000009396 hybridization Methods 0.000 description 27
- 230000004087 circulation Effects 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 230000009182 swimming Effects 0.000 description 20
- 238000005251 capillar electrophoresis Methods 0.000 description 19
- 206010008342 Cervix carcinoma Diseases 0.000 description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 description 16
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 16
- 201000010881 cervical cancer Diseases 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 230000035945 sensitivity Effects 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 238000001712 DNA sequencing Methods 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 238000009595 pap smear Methods 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 238000013507 mapping Methods 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 230000002255 enzymatic effect Effects 0.000 description 9
- 239000011347 resin Substances 0.000 description 9
- 229920005989 resin Polymers 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 108091033319 polynucleotide Proteins 0.000 description 8
- 102000040430 polynucleotide Human genes 0.000 description 8
- 239000002157 polynucleotide Substances 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 238000001502 gel electrophoresis Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000002594 sorbent Substances 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000012408 PCR amplification Methods 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 238000000137 annealing Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 208000007879 Atypical Squamous Cells of the Cervix Diseases 0.000 description 4
- 238000007399 DNA isolation Methods 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 241000341655 Human papillomavirus type 16 Species 0.000 description 4
- 239000004141 Sodium laurylsulphate Substances 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 210000003679 cervix uteri Anatomy 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 3
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N pentofuranose Chemical group OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 238000012797 qualification Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000011895 specific detection Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108091092878 Microsatellite Proteins 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 2
- 239000012807 PCR reagent Substances 0.000 description 2
- 241000589500 Thermus aquaticus Species 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000892 gravimetry Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- -1 methane amide Chemical class 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LOSIULRWFAEMFL-UHFFFAOYSA-N 7-deazaguanine Chemical compound O=C1NC(N)=NC2=C1CC=N2 LOSIULRWFAEMFL-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150061050 CIN1 gene Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 101150005988 cin2 gene Proteins 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012729 kappa analysis Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000011310 molecular screening test Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 208000029211 papillomatosis Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000004901 spalling Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000005382 thermal cycling Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19785008P | 2008-10-31 | 2008-10-31 | |
| US61/197,850 | 2008-10-31 | ||
| CN200980153183.8A CN102333892B (zh) | 2008-10-31 | 2009-10-26 | 用于检测人乳头瘤病毒的遗传标记 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980153183.8A Division CN102333892B (zh) | 2008-10-31 | 2009-10-26 | 用于检测人乳头瘤病毒的遗传标记 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105385784A true CN105385784A (zh) | 2016-03-09 |
Family
ID=42045205
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510671553.4A Pending CN105385784A (zh) | 2008-10-31 | 2009-10-26 | 用于检测人乳头瘤病毒的遗传标记 |
| CN200980153183.8A Expired - Fee Related CN102333892B (zh) | 2008-10-31 | 2009-10-26 | 用于检测人乳头瘤病毒的遗传标记 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200980153183.8A Expired - Fee Related CN102333892B (zh) | 2008-10-31 | 2009-10-26 | 用于检测人乳头瘤病毒的遗传标记 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8642261B2 (enExample) |
| EP (1) | EP2358915B1 (enExample) |
| JP (2) | JP2012507293A (enExample) |
| CN (2) | CN105385784A (enExample) |
| AU (1) | AU2009308943A1 (enExample) |
| CA (1) | CA2741762C (enExample) |
| ES (1) | ES2588251T3 (enExample) |
| HK (1) | HK1221749A1 (enExample) |
| WO (1) | WO2010051261A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013144344A2 (en) | 2012-03-30 | 2013-10-03 | Istituto Europeo Di Oncologia S.R.L. | Biomarkers for hpv infections, related diagnostic methods and kits |
| US20150376725A1 (en) * | 2013-09-04 | 2015-12-31 | Trovagene, Inc. | HPV Detection in Urine |
| US11062789B2 (en) | 2014-07-18 | 2021-07-13 | The Chinese University Of Hong Kong | Methylation pattern analysis of tissues in a DNA mixture |
| US10428391B2 (en) | 2015-07-27 | 2019-10-01 | The Johns Hopkins University | Method to use viral and host methylation markers for cervical cancer screening and triage in liquid prep, serum/plasma, and urine: PCR and sequencing based process methods |
| WO2018099418A1 (en) | 2016-11-30 | 2018-06-07 | The Chinese University Of Hong Kong | Analysis of cell-free dna in urine and other samples |
| WO2019013613A2 (es) | 2017-07-09 | 2019-01-17 | Hakken Enterprise Sa De Cv | Métodos y kits para determinar el riesgo de cáncer |
| CA3119928A1 (en) * | 2019-01-03 | 2020-07-09 | Hangzhou New Horizon Health Technology Co. Ltd. | Compositions and methods for urine sample storage and dna extraction |
| KR102286565B1 (ko) * | 2020-01-13 | 2021-08-05 | 대한민국 | 소변에서 결핵균 trDNA 추출용 올리고머 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997005164A1 (en) * | 1995-07-27 | 1997-02-13 | Csl Limited | Papillomavirus polyprotein constructs |
| US20020119478A1 (en) * | 1997-05-30 | 2002-08-29 | Diagen Corporation | Methods for detection of nucleic acid sequences in urine |
| WO2006066353A1 (en) * | 2004-12-23 | 2006-06-29 | Human Genetic Signatures Pty Ltd | Detection of human papilloma virus |
| EP1895018A2 (de) * | 2006-08-28 | 2008-03-05 | Genome Identification Diagnostics GmbH | Verfahren und Mittel zum Nachweis von humanen Papillomaviren |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2629458B2 (fr) * | 1987-07-31 | 1991-08-09 | Ire Celltarg Sa | Nouvelles sondes d'acides nucleiques specifiques de differents types de virus de papillome humain |
| US5447839A (en) * | 1988-09-09 | 1995-09-05 | Hoffmann-La Roche Inc. | Detection of human papillomavirus by the polymerase chain reaction |
| ATE474066T1 (de) * | 2005-11-15 | 2010-07-15 | Genoid Kft | Verfahren zum nachweis von pathogenen mittels molecular beacons |
| CN1814796A (zh) * | 2005-12-02 | 2006-08-09 | 浙江大学 | 一种用于26种人乳头瘤病毒的检测与分型的方法 |
| EP2184368A1 (en) * | 2008-11-07 | 2010-05-12 | DKFZ Deutsches Krebsforschungszentrum | Diagnostic transcript and splice patterns of HPV16 in different cervical lesions |
-
2009
- 2009-10-26 CN CN201510671553.4A patent/CN105385784A/zh active Pending
- 2009-10-26 EP EP09797216.0A patent/EP2358915B1/en not_active Not-in-force
- 2009-10-26 CN CN200980153183.8A patent/CN102333892B/zh not_active Expired - Fee Related
- 2009-10-26 US US13/126,081 patent/US8642261B2/en not_active Expired - Fee Related
- 2009-10-26 AU AU2009308943A patent/AU2009308943A1/en not_active Abandoned
- 2009-10-26 ES ES09797216.0T patent/ES2588251T3/es active Active
- 2009-10-26 CA CA2741762A patent/CA2741762C/en not_active Expired - Fee Related
- 2009-10-26 JP JP2011534663A patent/JP2012507293A/ja active Pending
- 2009-10-26 WO PCT/US2009/062114 patent/WO2010051261A2/en not_active Ceased
-
2014
- 2014-02-04 US US14/172,793 patent/US9453265B2/en not_active Expired - Fee Related
-
2015
- 2015-01-27 JP JP2015013489A patent/JP6092906B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-25 US US15/218,177 patent/US20170016078A1/en not_active Abandoned
- 2016-08-19 HK HK16109959.2A patent/HK1221749A1/zh unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997005164A1 (en) * | 1995-07-27 | 1997-02-13 | Csl Limited | Papillomavirus polyprotein constructs |
| US20020119478A1 (en) * | 1997-05-30 | 2002-08-29 | Diagen Corporation | Methods for detection of nucleic acid sequences in urine |
| WO2006066353A1 (en) * | 2004-12-23 | 2006-06-29 | Human Genetic Signatures Pty Ltd | Detection of human papilloma virus |
| EP1895018A2 (de) * | 2006-08-28 | 2008-03-05 | Genome Identification Diagnostics GmbH | Verfahren und Mittel zum Nachweis von humanen Papillomaviren |
Non-Patent Citations (7)
Also Published As
| Publication number | Publication date |
|---|---|
| US20140363807A1 (en) | 2014-12-11 |
| EP2358915B1 (en) | 2016-08-10 |
| HK1164940A1 (zh) | 2012-09-28 |
| CA2741762C (en) | 2018-04-03 |
| CN102333892A (zh) | 2012-01-25 |
| HK1221749A1 (zh) | 2017-06-09 |
| CN102333892B (zh) | 2015-11-25 |
| US20170016078A1 (en) | 2017-01-19 |
| JP6092906B2 (ja) | 2017-03-08 |
| US9453265B2 (en) | 2016-09-27 |
| EP2358915A2 (en) | 2011-08-24 |
| JP2015130863A (ja) | 2015-07-23 |
| US20110318727A1 (en) | 2011-12-29 |
| US8642261B2 (en) | 2014-02-04 |
| AU2009308943A1 (en) | 2010-05-06 |
| CA2741762A1 (en) | 2010-05-06 |
| WO2010051261A2 (en) | 2010-05-06 |
| ES2588251T3 (es) | 2016-10-31 |
| JP2012507293A (ja) | 2012-03-29 |
| WO2010051261A3 (en) | 2010-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9453265B2 (en) | Method for detection of high risk human papillomavirus | |
| US6218104B1 (en) | Method of detection of carcinogenic human papillomavirus | |
| Tham et al. | Diagnostic Sensitivity of Polymerase Chain Reaction and Southern Blot Hybridization for the Detection df Human Papillomavirus DNA in Biopsy Specimens from Cervical Lesions | |
| WO1992001815A1 (en) | Method for the diagnosis of human pappiloma virus type 16 using the polymerase chain reaction | |
| Feoli‐Fonseca et al. | Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR‐direct sequencing approach | |
| Tornesello et al. | Prevalence of alpha‐papillomavirus genotypes in cervical squamous intraepithelial lesions and invasive cervical carcinoma in the Italian population | |
| Burmer et al. | Comparative analysis of human papillomavirus detection by polymerase chain reaction and Virapap/Viratype kits | |
| Schadendorf et al. | Detection of human papillomaviruses in paraffin-embedded condylomata acuminata—comparison of immunohistochemistry, in situ hybridization, and polymerase chain reaction | |
| CN113584225B (zh) | 一种检测hpv病毒的引物和探针组合及其分型检测的试剂、应用 | |
| Miller et al. | Human papillomavirus type 16 DNA in esophageal carcinomas from Alaska natives | |
| Rakoczy et al. | Time trends in the prevalence of human papillomavirus infections in archival Papanicolaou smears: analysis by cytology, DNA hybridization, and polymerase chain reaction | |
| US8399652B2 (en) | Primers and probes for detecting genital HPV genotypes | |
| WO2020109866A1 (en) | Association between integration of viral as hpv or hiv genomes and the severity and/or clinical outcome of disorders as hpv associated cervical lesions or aids pathology | |
| CN105518155A (zh) | 尿液中的hpv检测 | |
| US20030129585A1 (en) | Detection of human papillomaviruses | |
| WO2018207022A1 (en) | Association between integration of high-risk hpv genomes detected by molecular combing and the severity and/or clinical outcome of cervical lesions | |
| Tornesello et al. | Human papillomavirus infection in urine samples from male renal transplant patients | |
| US20040248085A1 (en) | General primers and process for detecting diverse genotypes of human papillomavirus by PCR | |
| Chinchai et al. | Comparison between direct sequencing and INNO-LiPA methods for HPV detection and genotyping in Thai Women | |
| EP2362916B1 (en) | Hpv types and variants associated with cervical cancer and the uses thereof | |
| HK1164940B (en) | A genetic marker for detection of human papillomavirus | |
| Inoue et al. | Detection and typing of genital high-risk HPV DNAs in cervical scrapes using the E6/E7-specific consensus PCR | |
| KR101459074B1 (ko) | 인유두종바이러스 유전자형 분석용 ｄｎａ 칩， 이를 포함하는 키트 및 이를 이용한 인유두종바이러스 유전자형 분석방법 | |
| Soltanahmadi et al. | MOLECULAR DIAGNOSIS OF HUMAN PAPILLOMAVIRUS (HPV) GENOTYPES IN TEHRAN CITY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1221749 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160309 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1221749 Country of ref document: HK |